AL-LAD

N6-allyl-6-norlysergic acid diethylamide

6-allyl-6-nor-LSD, N-allyl-nor-LSD

Psychoactive Class

Chemical Class

AL-LAD is a semi-synthetic psychedelic of the lysergamide class and a close structural analog of LSD. First described in scientific literature during the 1970s,¹ it was further investigated by Andrew J. Hoffman and David Nichols in 1984² and subsequently documented by Alexander Shulgin in TiHKAL.³ It entered the research chemical market around 2013 as a grey-market alternative to LSD.⁴ Users often report enhanced visual activity with comparatively reduced cognitive intensity relative to LSD.³

Dosage & Duration

Dosage

Threshold~20 ug

Light20-75 ug

Moderate75-175 ug

Strong175-250 ug

Heavy250+ ug

Duration

Onset20-60 minutes

Come Up30-60 minutes

Peak2.5-5 hours

Offset2-3 hours

After Effects2-18 hours

Total7-10 hours

Subjective Effects

Effects vary widely by individual, dose, and context.

Physical

Increased bodily control

Cognitive

In comparison to other psychedelics such as Psilocin, LSA and Ayahuasca, AL-LAD is significantly more stimulating and fast paced in terms of the specific style of thought stream which it produces and contains a large number of potential effects.

Enhancement of current mind state Acceleration of thought Feelings of fascination, importance and awe Time distortion Introspection Déjà vu Multiple thought streams Removal of cultural filter Conceptual thinking Ego suppression, loss and death Thought loops Feelings of interdependent opposites Delusions States of unity and interconnectedness

Visual

Distortions

Tracers After images Depth Perception Distortions Symmetrical texture repetition Colour shifting Scenery slicing

Enhancements

Increased visual acuity Enhancement of colour Enhanced pattern recognition

Geometry

The visual geometry that is present throughout this trip can be described as more similar in appearance to that of 2C-B or 2C-I than Psilocin, LSA or DMT. It can be comprehensively described through its variations as primarily intricate in complexity, algorithmic in form, unstructured in organization, brightly lit, colourful in scheme, organic in feel, multicoloured in scheme, flat in shading, soft in its edges, large in size, slow in speed, smooth in motion, round in its corners, unimmersive in depth and consistent in intensity. At higher dosages, it consistently results in states of Level 8A visual geometry over Level 8B.

Hallucinatory States

AL-LAD is capable of producing a full range of low and high level hallucinatory states in a fashion that is significantly less consistent and reproducible than that of many other commonly used psychedelics.

Transformations

Auditory

The auditory effects of AL-LAD are common in their occurrence and exhibit a full range of effects.

Enhancements Distortions Hallucinations

Forked from Subjective Effect Documentation

by Josie KinsJuly 2014.

Reagent Testing

Loading reagent data

Expected colorimetric results are being prepared.

Pharmacology

Pharmacodynamics

AL-LAD acts as an agonist at the serotonin 5-HT2A receptor, which is considered the primary mechanism underlying its psychedelic effects.⁴ It displays high binding affinity for this receptor⁵⁴, though sources disagree on whether it functions as a full agonist or a partial agonist. AL-LAD also interacts with other serotonin receptors in the 5-HT1 family⁵ and shows affinity for dopamine D1 and D2 receptors.⁴

Pharmacokinetics

Limited formal pharmacokinetic data is available for AL-LAD. It appears to be metabolized more readily than its parent compound LSD, which is consistent with its comparatively compressed duration of effects.

Metabolitesnone documented yet

Interactions

Dangerous

Highest risk

These combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.

Lithium

Unsafe

Avoid

There is considerable risk of physical harm when taking these combinations, they should be avoided where possible.

Tramadol

Caution

Use caution

These combinations are not usually physically harmful, but may produce undesirable effects, such as physical discomfort or overstimulation. Extreme use may cause physical health issues. Synergistic effects may be unpredictable. Care should be taken when choosing to use this combination.

AmphetaminesCannabisCocaineDiphenhydramineMephedronePregabalin

TripSit

Tolerance

Full Tolerance

Tolerance to the effects of AL-LAD develops almost immediately after ingestion. As with other serotonergic psychedelics, repeated dosing within a short timeframe will result in significantly diminished effects⁶ unless the dose is substantially increased.

Baseline Reset

Full baseline tolerance is typically restored after approximately 14 days of abstinence from AL-LAD and other serotonergic psychedelics. Some sources suggest noticeable effects may return after 4-7 days, though full sensitivity requires the longer abstinence period.

Half Tolerance

Approximately 5-7 days after ingestion, tolerance is estimated to reduce to roughly half of its peak level.

Cross Tolerance

Serotonergic psychedelics (LSD, psilocybin, mescaline, DMT), Other 5-HT2A agonists

Harm Potential

Addiction & Dependence

Psychological

Extremely Low

AL-LAD is non-habit forming and the desire to use it can actually decrease with use.⁷⁸ It is considered self-regulating in the same manner as LSD and other classic psychedelics.

Physical

Extremely Low

No physical dependence or withdrawal symptoms have been documented. As with LSD, AL-LAD does not appear to produce physical dependence⁷, though formal studies have not been conducted.

Psychosis Risk

AL-LAD may act as a potential trigger for psychotic episodes in those with underlying psychiatric conditions. Those with a personal or family history of mental illness are advised not to use this substance.⁹ Delusions and adverse psychological reactions become more likely at higher doses, though overt psychosis appears uncommon in otherwise healthy individuals using the substance alone.

Seizure Risk

Seizures are rare but have been reported, primarily in those who are genetically predisposed to them,¹⁰ particularly when accompanied by physically taxing conditions such as dehydration, fatigue, or undernourishment. Those with preexisting seizure disorders should avoid AL-LAD.

History & Culture

AL-LAD was first synthesized and described in the scientific literature in 1976.⁴ The compound received further attention in 1984 when researchers Andrew J. Hoffman and David Nichols investigated it as part of a broader series of LSD analogues, which also included ETH-LAD…

Trip Reports

Legality

International

1961 Single Convention: AL-LAD is not individually scheduled.

1971 Convention on Psychotropic Substances: AL-LAD is not individually scheduled.

1988 Convention: AL-LAD is not listed in precursor Tables I or II.

By Country

United StatesIllegal (analog/blanket ban)Federal analogue treatment

21 U.S.C. §§ 802(32), 813²¹

Current federal or national law provides the stated AL-LAD control mechanism in United States; analogue treatment remains fact- and context-dependent where applicable.

CanadaIllegal (analog/blanket ban)LSD analogue control

Controlled Drugs and Substances Act, Schedule III and analogue definition¹²

Canada controls LSD and its analogues through the Controlled Drugs and Substances Act; AL-LAD falls under analogue treatment rather than a separately named listing.

FinlandBannedCitation needed

Listed in a government decree banning psychoactive substances from the consumer market.¹⁴

GermanyRestrictedNpSG substance-group control

Neue-psychoaktive-Stoffe-Gesetz, Anlage¹⁶

Current federal or national law provides the stated AL-LAD control mechanism in Germany; analogue treatment remains fact- and context-dependent where applicable.

LatviaControlled (as analogue)Citation needed

Although not officially scheduled by name, controlled as an LSD structural analogue¹⁷ under an amendment enacted June 1, 2015.

SwitzerlandIllegal (Verzeichnis E)Citation needed

Specifically named as a controlled substance under Verzeichnis E, effective December 1, 2015, as part of a broader scheduling of 21 novel psychoactive substances.

United KingdomIllegalClass A controlled lysergamide

Misuse of Drugs Act 1971 (Amendment) Order 2015²⁰

Current federal or national law provides the stated AL-LAD control mechanism in United Kingdom; analogue treatment remains fact- and context-dependent where applicable.

AustriaUnscheduled (potentially controlled as analogue)Citation needed

Not specifically scheduled, but may fall under the Neue-Psychoaktive-Substanzen-Gesetz (NPSG) as a structural analogue of LSD.¹¹

DenmarkIllegalCitation needed

Specifically named on the list of controlled substances¹³ as of August 25, 2015.

FranceIllegalCitation needed

Prohibited under national drug control legislation.¹⁵

JapanControlled substanceCitation needed

Designated as a controlled substance effective February 28, 2020.

SwedenSchedule I (Narcotic)Citation needed

Added to the Narcotic Drugs Punishments Act under Schedule I (substances without accepted medical use) on January 26, 2016.¹⁸ Listed in Medical Products Agency regulation HSLF-FS 2015:35 under multiple names including 6-allyl-6-nor-LSD.¹⁸

TurkeyIllegalCitation needed

Prohibited under national drug control legislation as of February 2016.¹⁹

References

Source Pages

Citations

Reviewed & approved
Reviewed, edited, and approved by subject-matter expert Lyrea.
Automated synthesis
Information aggregated and synthesized using an autonomous workflow built by Josie Kins.

Suggest an edit

Spotted a mistake, an outdated claim, or something missing from the AL-LAD article? Send the editors a private note. Feedback lands in a moderation queue and is never shown on the site.

AL-LAD

N6-allyl-6-norlysergic acid diethylamide

6-allyl-6-nor-LSD, N-allyl-nor-LSD

Psychoactive Class

Psychedelic

Chemical Class

Lysergamide